Severity
Moderate
FDA Drug recall · Reported March 7, 2018
Failed Stability Specifications: Product stability testing results did not meet specifications for iron content.
Allergan recalled INFeD (Iron Dextran Injection USP) 100 mg elemental iron/2 ml (50 mg/mL), Rx Only, packag… - a moderate-severity action.
INFeD (Iron Dextran Injection USP) 100 mg elemental iron/2 ml (50 mg/mL), Rx Only, packag… was recalled by Allergan in March 7, 2018. Reason: Failed Stability Specifications: Product stability testing results did not meet specifications for iron conte…. Check the official notice for the remedy. Verify recall #D-0545-2018 with the FDA Drug before acting.
The recall
Allergan issued this moderate-severity FDA Drug recall-Failed Stability Specifications: Product stability testing results did not meet specifications for iron conte….
Sourced from official FDA Drug enforcement records. Verify recall #D-0545-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0545-2018) was formally reported on March 7, 2018, with the manufacturer initiating the action on December 13, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. Allergan is listed as the recalling firm, operating out of Madison, NJ. Federal records list the affected scope as 163,694 cartons.
The documented reason for this recall is: Failed Stability Specifications: Product stability testing results did not meet specifications for iron content. Distribution data in the federal record shows the product reached: Product was distributed nationwide in the USA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
163,694 cartons
Related Recalls
6
5 from same agency
INFeD (Iron Dextran Injection USP) 100 mg elemental iron/2 ml (50 mg/mL), Rx Only, packaged in a) single dose vials, (NDC 52544-931-07), b) carton of 10 x 2 ml Single Dose Vials (NDC 52544-931-02) Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054, Manufactured by: Patheon Italia S.p.A. Ferentino, Italy 03013.
Failed Stability Specifications: Product stability testing results did not meet specifications for iron content.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0545-2018 |
| Date reported | March 7, 2018 |
| Date initiated | December 13, 2017 |
| Recalling firm | Allergan |
| Firm location | Madison, NJ |
| Affected scope | 163,694 cartons |
| Distribution | Product was distributed nationwide in the USA. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 7, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.